1. Home
  2. CGTX vs ALUR Comparison

CGTX vs ALUR Comparison

Compare CGTX & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.70

Market Cap

158.8M

Sector

Health Care

ML Signal

HOLD

ALUR

Allurion Technologies Inc.

HOLD

Current Price

$1.66

Market Cap

15.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGTX
ALUR
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
158.8M
15.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CGTX
ALUR
Price
$1.70
$1.66
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$2.88
$9.25
AVG Volume (30 Days)
933.6K
124.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$17,208,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$9.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$1.02
52 Week High
$3.83
$16.81

Technical Indicators

Market Signals
Indicator
CGTX
ALUR
Relative Strength Index (RSI) 53.10 52.59
Support Level $1.69 $1.61
Resistance Level $1.77 $1.75
Average True Range (ATR) 0.12 0.17
MACD 0.01 0.04
Stochastic Oscillator 75.58 84.42

Price Performance

Historical Comparison
CGTX
ALUR

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Share on Social Networks: